<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02267915</url>
  </required_header>
  <id_info>
    <org_study_id>GELTAMO-MAN2</org_study_id>
    <nct_id>NCT02267915</nct_id>
  </id_info>
  <brief_title>Phase II of Efficacy and Toxicity of Maintenance Sub. Rituximab After Induction in Relapsed MCL and Non-eligible HSCT</brief_title>
  <acronym>MAN2</acronym>
  <official_title>An Open Multicenter Phase II Study of Efficacy and Toxicity of Maintenance Subcut. Rituximab After Induction With Rituximab in Patients With Relapsed or Refractory Mantle-cell Lymphoma Non-eligible for HSCT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Primary endpoint: Time to relapse/progression (TTP) after achieving a complete or
           partial response with the (R-GemOxD)-induction therapy

        2. Secondary endpoints:

             1. Quality of response obtained after subcutaneous Rituximab maintenance.

             2. Progression-Free Survival (PFS)

             3. Overall Survival (OS)

             4. Time to Next Therapy (TTNT)

             5. Value of MRD in the disease outcome

             6. Toxicity
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase II trial evaluating the role of maintenance with subcutaneous Rituximab in
      patients with stage II-IV relapsed or refractory mantle-cell lymphoma with complete or
      partial response after the administration of a salvage regimen with R-GemOx-D.

      Before the study start and in order to standardize the results, the same R-GemOx-D salvage
      regimen will be used: Rituximab: 375 mg/m2 on day 1, Gemcitabine: 1000 mg/m2 on day 2 (over
      30 minutes) and Oxaliplatin: 100 mg/m2 on day 2 (over 3 hours), Dexamethasone 20 mg on day
      1-3. Cycles should be repeated every 14 days, up to 8 cycles.

      Patients who present a complete or partial response, after the salvage therapy, will start
      the study receiving subcutaneous Rituximab maintenance at dose of: 1400 mg every 2 months for
      2 years; the study treatment will start 6-8 weeks after finishing the salvage therapy.

      Patients will be evaluated every 2 months during treatment study phase and every 4 months in
      the follow up phase. More details in Appendix 1 (Schedule of Assessments)
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>March 2015</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to progression, (Measured from achievement of response -partial or complete- to to disease progression)</measure>
    <time_frame>2 YEARS</time_frame>
    <description>2 years after last patient randomized in maintenance</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Mantle-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>subcutaneous rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MabThera 1400 mg solution for subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>subcutaneous Rituximab</intervention_name>
    <description>MabThera 1400 mg solution for subcutaneous injection</description>
    <arm_group_label>subcutaneous rituximab</arm_group_label>
    <other_name>MABTHERA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Basal diagnosis of mantle-cell lymphoma in relapse or refractory.

          -  Achievement of a CR or PR after salvage therapy with R-GemOxD (6 to 8 cycles) as
             previously described4-5.

          -  Age &gt; 18 years.

          -  One or maximum two prior chemotherapy or immunochemotherapy lines.

          -  Patients should not be considered candidates for high-dose chemotherapy and autologous
             stem-cell transplantation.

          -  No clinical evidence of CNS involvement

          -  Signed informed consent

          -  Serum creatinine less than 2 and/or bilirrubin less than 2.5 UNL.

          -  Pregnant or lactating woman. FCBP must agree to ongoing pregnancy testing during the
             course or study and commit to use effective contraception during the study

        Exclusion Criteria:

          -  Prior organ transplantation.

          -  HIV positive.

          -  HBV related disease

          -  Any serious active disease or co-morbid medical condition (according to the
             investigator's decision)

          -  Any history of cancer during the last 5 years, with the exception of non-melanoma skin
             tumors or stage 0 cervix carcinoma.

          -  Less than 50% of tumor response.

          -  Platelet counts less than 50 x 109/L.

          -  Neutrophil counts less than 1.0 x 109/L.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andres Lopez, DOCTOR</last_name>
    <role>Study Director</role>
    <affiliation>Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Geltamo Investigational Site</name>
      <address>
        <city>Gijon</city>
        <state>Asturias</state>
        <zip>33394</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geltamo Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>LA Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geltamo Investigational Site</name>
      <address>
        <city>Alcorcon</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geltamo Investigational Site</name>
      <address>
        <city>Majadahonda</city>
        <state>Madrid</state>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geltamo Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geltamo Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geltamo Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geltamo Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geltamo Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geltamo Investigational Site</name>
      <address>
        <city>Burgos</city>
        <zip>09006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geltamo Investigational Site</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geltamo Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28031</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geltamo Investigational Site</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geltamo Investigational Site</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geltamo Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2014</study_first_submitted>
  <study_first_submitted_qc>October 15, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <last_update_submitted>April 24, 2018</last_update_submitted>
  <last_update_submitted_qc>April 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Relapsed or refractory patients with mantle-cell lymphoma</keyword>
  <keyword>Progression after high-dose chemotherapy and autologous HPT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Mantle-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

